ClearPoint Neuro, Inc. is a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. The Company’s flagship product is the ClearPoint Neuro Navigation System. Its initial product offering, the ClearPoint system, is an integrated system comprised of capital equipment and disposable products, designed to allow minimally invasive procedures in the brain to be performed in a magnetic resonance imaging (MRI) suite. The ClearPoint Array Neuro Navigation System and its principal disposable component is designed to be deployed in an operating room setting while also being usable in an MRI suite. It is engaged with healthcare and research centers in North America, Europe, Asia, and South America. It also provides solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide.
Ticker SymbolCLPT
Company nameClearpoint Neuro Inc
IPO dateJul 03, 2019
CEOMr. Joseph Michael Burnett
Number of employees115
Security typeOrdinary Share
Fiscal year-endJul 03
Address120 S. Sierra Avenue
CitySOLANA BEACH
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code92075
Phone19499006833
Websitehttps://www.clearpointneuro.com/
Ticker SymbolCLPT
IPO dateJul 03, 2019
CEOMr. Joseph Michael Burnett
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data